Befotertinib is a chemical compound under investigation as an active pharmaceutical ingredient. It is being studied in clinical trials for advanced EGFR-mutant lung cancer.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1835667-63-4
Osimertinib
pharmaceutical raw material
Osimertinib mesylate
pharmaceutical raw material
Ethacridine lactate
pharmaceutical raw material
Formoterol fumarate dihydrate
pharmaceutical raw material
Pyrilamine tannate
pharmaceutical raw material
Salcaprozic acid
pharmaceutical raw material
Mobocertinib
pharmaceutical raw material
Mobocertinib succinate
pharmaceutical raw material
N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-[1-(2,2,2-trifluoroethyl)indol-3-yl]pyrimidin-2-yl]amino]phenyl]prop-2-enamide
USOCZVZOXKTJTI-UHFFFAOYSA-N
CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=CC(=N2)C3=CN(C4=CC=CC=C43)CC(F)(F)F)OC